Company News: Pfizer

Share this article:
Pfizer said last night that it suspended the osteoarthritis clinical program for investigational compound tanezumab following a certain number of reports that tanezumab patients had their osteoarthritis worsen leading to joint replacement. The product was being studied as a way to treat pain associated with the condition. Pfizer said the adverse event has not been observed in non-osteoarthritis patient populations taking tanezumab. Pfizer said the monoclonal antibody is still being studied in conditions such as cancer pain, low back pain and pain associated with diabetes.
Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.